Promis Neurosciences (PMN) to Release Earnings on Thursday

Promis Neurosciences (NASDAQ:PMN) is anticipated to release its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 19, 2025 at 6:00 PM ET.

Promis Neurosciences (NASDAQ:PMN) last announced its earnings results on Wednesday, August 13th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.07). On average, analysts expect Promis Neurosciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Promis Neurosciences Stock Performance

NASDAQ:PMN opened at $0.39 on Tuesday. The stock’s fifty day moving average is $0.44 and its 200 day moving average is $0.52. Promis Neurosciences has a fifty-two week low of $0.36 and a fifty-two week high of $1.59. The firm has a market capitalization of $20.92 million, a PE ratio of -1.85 and a beta of -0.22.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Leede Financial upgraded shares of Promis Neurosciences to a “moderate buy” rating in a research report on Monday, July 21st. HC Wainwright started coverage on shares of Promis Neurosciences in a research note on Monday, July 14th. They set a “buy” rating and a $4.00 price target for the company. Wall Street Zen downgraded shares of Promis Neurosciences to a “strong sell” rating in a report on Saturday, October 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Promis Neurosciences in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $4.33.

Promis Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.